# EDGAR Filing Document

**Accession Number:** 0000055529
**File Stem:** 0000055529-25-000033
**Filing Date:** 2025-9
**Character Count:** 27034
**Document Hash:** e60acde69a5f380795d9bb65fe08c162
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000055529-25-000033.hdr.sgml**: 20250910

**ACCESSION NUMBER**: 0000055529-25-000033

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250910

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250910

**DATE AS OF CHANGE**: 20250910

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** KEWAUNEE SCIENTIFIC CORP /DE/
- **CENTRAL INDEX KEY:** 0000055529
- **STANDARD INDUSTRIAL CLASSIFICATION:** LABORATORY APPARATUS & FURNITURE [3821]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 380715562
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0430

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-05286
- **FILM NUMBER:** 251306022

**BUSINESS ADDRESS:**
- **STREET 1:** 2700 W FRONT ST
- **CITY:** STATESVILLE
- **STATE:** NC
- **ZIP:** 28677
- **BUSINESS PHONE:** 7048737202

**MAIL ADDRESS:**
- **STREET 1:** P O BOX 1842
- **CITY:** STATESVILLE
- **STATE:** NC
- **ZIP:** 28687-1842

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** KEWAUNEE SCIENTIFIC EQUIPMENT CORP /DE/
- **DATE OF NAME CHANGE:** 19861216

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** KEWAUNEE MANUFACTURING CO
- **DATE OF NAME CHANGE:** 19680108

?xml version='1.0' encoding='ASCII'? kequ-20250910

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM 8-K**

**Current Report Pursuant to Section 13 or 15(d) of**

**The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): September 10, 2025**

**Kewaunee Scientific Corporation**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **0-5286** | **38-0715562** |
| **(State or other jurisdiction of<br>incorporation or organization)** | **(Commission File<br>Number)** | **(IRS Employer<br>Identification No.)** |

---

**2700 West Front Street**

**Statesville, NC 28677**

**(Address of principal executive offices) (Zip Code)**

**Registrant's telephone number, including area code: (704) 873-7202**

**N/A**

**(Former name or former address, if changed since last report)**

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common Stock, $2.50 par value** | **KEQU** | **The Nasdaq Global Market** |

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the

Exchange Act. ☐

------

**Item 2.02 Results of Operations and Financial Condition**

On September 10, 2025, Kewaunee Scientific Corporation issued a press release announcing its financial results for the first quarter of fiscal year 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01. Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(d) Exhibits**

---

| | |
|:---|:---|
| &nbsp;&nbsp;**<u>Exhibit No.</u>** | &nbsp;&nbsp;**<u>Description</u>** |
| &nbsp;&nbsp;99.1 | &nbsp;&nbsp;<u>[Press Release of Kewaunee Scientific Corporation dated](prfy26q1earningsrelease.htm)[Septe](prfy26q1earningsrelease.htm)[mber](prfy26q1earningsrelease.htm)[1](prfy26q1earningsrelease.htm)[0](prfy26q1earningsrelease.htm)[, 2025.](prfy26q1earningsrelease.htm)</u> |
| &nbsp;&nbsp;104 | &nbsp;&nbsp;Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

------

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | KEWAUNEE SCIENTIFIC CORPORATION<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Registrant) | KEWAUNEE SCIENTIFIC CORPORATION<br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (Registrant) |
| Date: September 10, 2025 | By | /s/ Donald T. Gardner III |
| | | Donald T. Gardner III |
| | | Vice President, Finance |
| | | Chief Financial Officer |

---

## Exhibit 99.1

![logo_stackedxdark.jpg](logo_stackedxdark.jpg)

**Kewaunee Scientific Reports**

**Results for First Quarter of Fiscal Year 2026**

Exchange:&nbsp;&nbsp;&nbsp;&nbsp;NASDAQ (KEQU)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contact:&nbsp;&nbsp;&nbsp;&nbsp;Donald T. Gardner III

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;704/871-3274

STATESVILLE, N.C. September 10, 2025 – PRNewswire / Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its first quarter ended July 31, 2025.

**Fiscal Year 2026 First Quarter Results:**

Sales during the first quarter of fiscal year 2026 were $71,104,000, an increase of 46.9% compared to sales of $48,393,000 from the prior year's first quarter. Pre-tax earnings for the quarter were $3,920,000 compared to $2,430,000 for the prior year quarter, an increase of 61.3%. Net earnings were $3,093,000 compared to net earnings of $2,193,000 for the prior year quarter. EBITDA<sup>1</sup> for the quarter was $6,320,000 compared to $3,325,000 for the prior year quarter. Diluted earnings per share were $1.04 compared to diluted earnings per share of $0.74 in the prior year quarter.

The Company's order backlog was $205.0 million on July 31, 2025, as compared to $159.4 million on July 31, 2024, and $214.6 million on April 30, 2025.

**<u>Domestic Segment</u>** - Domestic sales for the quarter were $54,352,000, an increase of 53.0% from sales of $35,523,000 in the prior year quarter. Domestic segment net earnings were $4,722,000 compared to $2,871,000 in the prior year quarter. Domestic segment EBITDA was $7,576,000 compared to $4,738,000 for the prior year quarter. The increase in Domestic sales and earnings was driven by the incorporation of Nu Aire's results, steady manufacturing volumes, improved productivity, and cost management actions.

**<u>International Segment</u>** - International sales for the quarter were $16,752,000, an increase of 30.2% from sales of $12,870,000 in the prior year quarter. International segment net earnings were $643,000 compared to $463,000 in the prior year quarter. International segment EBITDA was $1,055,000 compared to $696,000 for the prior year quarter. The impact of customer site delays experienced during most of the prior fiscal year began decreasing during the fourth quarter of fiscal year 2025, resulting in increased deliveries and billings for the first quarter of fiscal year 2026 compared to the comparable prior year period.

**<u>Corporate Segment</u>** – Corporate segment pre-tax net loss was $3,058,000 for the quarter, as compared to a pre-tax net loss of $1,992,000 in the prior year quarter. Corporate segment EBITDA for the quarter was ($2,311,000) compared to corporate segment EBITDA of ($2,109,000) for the prior year quarter. Corporate segment EBITDA remained relatively stable year over year, despite the inclusion of $730,000 of costs in the prior year period results directly related to the acquisition of Nu Aire, Inc., which closed on November 1, 2024. In the current

<sup>1</sup> EBITDA is a non-GAAP financial measure. See the table below for a reconciliation of EBITDA and segment EBITDA to net earnings (loss), the most directly comparable GAAP measure.

CORPORATE OFFICES ● P. O. BOX 1842, STATESVILLE, NORTH CAROLINA 28687-1842 ● 2700 WEST FRONT STREET, STATESVILLE, NORTH CAROLINA 28677-2927

PHONE 704-873-7202 ● FAX 704-873-1275

------

year period, the Company incurred costs related to its strategic investment in its Corporate platform. These investments include increased compliance costs related to the anticipated triggering of Sarbanes-Oxley 404(b) requirements and strategic investments in people, processes, and technology to continue to build out the Company's Corporate platform in order to support future anticipated growth.

Total cash on hand on July 31, 2025, was $20,441,000, as compared to $17,164,000 on April 30, 2025. Working capital was $66,662,000, as compared to $56,012,000 at the end of the first quarter last year and $64,651,000 on April 30, 2025.

The Company had short-term debt of $4,294,000 as of July 31, 2025, as compared to $4,773,000 on April 30, 2025. Long-term debt was $60,269,000 on July 31, 2025, as compared to $60,730,000 on April 30, 2025. The building lease from the Company's December 2021 sale-leaseback transaction accounts for $26,420,000 of the long-term debt on July 31, 2025, and $26,632,000 of the long-term debt on April 30, 2025. Long-term debt, net of the sale-leaseback transaction, was $33,849,000 on July 31, 2025, as compared to $34,098,000 on April 30, 2025. The Company's debt-to-equity ratio on July 31, 2025, was 0.94-to-1, as compared to 0.99-to-1 on April 30, 2025. The Company's debt-to-equity ratio, net of the sale-leaseback transaction, on July 31, 2025, was 0.54-to-1, as compared to 0.57-to-1 on April 30, 2025.

"Our Domestic and International segments delivered solid financial performance in the first quarter despite challenging market conditions as a result of uncertain government policy, evolving tariff structures and broader geopolitical upheaval," said Thomas D. Hull III, Kewaunee's President and Chief Executive Officer. "While our overall backlog remains near historically high levels, we are experiencing volatility in project delivery timelines that we expect will cause uneven performance by quarter for the balance of fiscal year 2026, likely starting in the second quarter. This is a reality of both the uncertainty in the market, and the nature of construction-related manufacturing, where project timing often shifts, causing peaks and valleys in production schedules."

"Kewaunee is focused on growth, both organically and inorganically, and is committed to making strategic investments in the people, processes, and technology that will support and enable this growth in a sustainable manner. These important investments are accounted for in the Corporate segment and, while some of the costs are expected to be non-recurring in nature, many of them will not be. Though this will place pressure on earnings growth in the near term, we believe it will position Kewaunee for rapid and sustained growth in the future, allowing us to gain leverage on these investments over the long term."

"Despite our anticipation of uneven quarterly performance for the remainder of fiscal year 2026, and increasing strategic investment in the Corporate platform, we expect to deliver better unadjusted EBITDA in fiscal year 2026 than we did in fiscal year 2025. We are confident in the strategies we are employing and the long-term health of the business."

------

**<u>EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA Reconciliation</u>**

*(Unaudited)*

*($ in thousands)*

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Quarter Ended July 31, 2024** | **Domestic** | **International** | **Corporate** | **Consolidated** |
| Net Earnings (Loss) | $2871 | $463 | $(1141) | $2193 |
| Add/(Less): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest Expense | 441 | 21 | 10 | 472 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest Income |  | (174) | (173) | (347) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income Taxes | 764 | 279 | (851) | 192 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and Amortization | 662 | 107 | 46 | 815 |
| EBITDA | $4738 | $696 | $(2109) | $3325 |
| &nbsp;&nbsp;&nbsp;&nbsp;Professional Fees<sup>2</sup> |  |  | 730 | 730 |
| Adjusted EBITDA | $4738 | $696 | $(1379) | $4055 |
| **Quarter Ended July 31, 2025** | **Domestic** | **International** | **Corporate** | **Consolidated** |
| Net Earnings (Loss) | $4722 | $643 | $(2272) | $3093 |
| Add/(Less): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest Expense | 313 | 13 | 732 | 1058 |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest Income |  | (131) | (10) | (141) |
| &nbsp;&nbsp;&nbsp;&nbsp;Income Taxes | 1113 | 434 | (786) | 761 |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and Amortization | 1428 | 96 | 25 | 1549 |
| EBITDA | $7576 | $1055 | $(2311) | $6320 |
| &nbsp;&nbsp;&nbsp;&nbsp;Professional & Other Fees<sup>3</sup> |  |  | 224 | 224 |
| Adjusted EBITDA | $7576 | $1055 | $(2087) | $6544 |

---

<sup>2</sup> Professional and other fees incurred during the three months ended July 31, 2024 related to the Company's acquisition of Nu Aire, Inc. ("Nu Aire"), which closed on November 1, 2024

<sup>3</sup> Professional and other fees incurred during the three months ended July 31, 2025 related to the Company's integration of its newly acquired subsidiary, Nu Aire

------

**<u>Adjusted Consolidated Statement of Operations Reconciliation</u>**

*(Unaudited)*

*($ in thousands, except per share amounts)*

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended July 31,** | **Three Months Ended July 31,** | **Three Months Ended July 31,** | **Three Months Ended July 31,** |
| | **As Reported 2025** | **Professional & Other Fees**<sup>4</sup> | **Adjusted<br>2025** | **Adjusted 2024** |
| Net sales | $**71104** | $**—** | $**71104** | $48393 |
| Cost of products sold | **50174** | **—** | **50174** | 35905 |
| Gross profit | **20930** | **—** | **20930** | 12488 |
| Operating expenses | **16120** | **224** | **15896** | 9183 |
| Operating profit | **4810** | **224** | **5034** | 3305 |
| Other income, net | **168** | **—** | **168** | 327 |
| Interest expense | **(1058)** | **—** | **(1058)** | (472) |
| Profit before income taxes | **3920** | **224** | **4144** | 3160 |
| Income tax (benefit) expense | **761** | **49** | **810** | 345 |
| Net earnings | **3159** | &nbsp;&nbsp;&nbsp;**175** | &nbsp;&nbsp;&nbsp;**3334** | 2815 |
| Less: Net earnings attributable to the non-controlling interest | **66** | **—** | **66** | 45 |
| Net earnings attributable to Kewaunee Scientific Corporation | $**3093** | $**175** | $**3268** | $2770 |
| Net earnings per share attributable to Kewaunee Scientific Corporation stockholders |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | $**1.08** | $**0.06** | $**1.15** | $0.97 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | $**1.04** | $**0.06** | $**1.10** | $0.93 |

---

<sup>4</sup> Professional and other fees incurred during the three months ended July 31, 2025 related to the Company's integration of its newly acquired subsidiary, Nu Aire, including the estimated tax impact

------

*About Non-GAAP Measures* 

The Company includes non-GAAP financial measures such as adjusted net earnings and adjusted net earnings per share, in the information provided with this press release as supplemental information relating to its operating results. Adjusted net earnings represents GAAP net earnings adjusted for professional and other fees related to the integration of the Company's newly acquired subsidiary, Nu Aire, Inc., and the corresponding tax impact. This financial information is not in accordance with, or an alternative for, GAAP-compliant financial information and may be different from the operating or non-GAAP financial information used by other companies. The Company believes that this presentation of adjusted net earnings and adjusted net earnings per share provides useful information to investors regarding certain additional financial and business trends relating to its financial condition and results of operations.

EBITDA and Segment EBITDA are calculated as net earnings (loss), less interest expense and interest income, income taxes, depreciation, and amortization. Adjusted EBITDA and Adjusted Segment EBITDA are calculated as EBITDA or Segment EBITDA less the impact of the professional and other fees related to the Company's integration of its newly acquired subsidiary, Nu Aire, Inc., as discussed in more detail above. We believe EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA allow management and investors to compare our performance to other companies on a consistent basis without regard to interest expense and interest income, income taxes, depreciation, amortization or the costs incurred related to the integration of Nu Aire, Inc., which can vary significantly between companies depending upon many factors. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA are not calculations based upon generally accepted accounting principles, and the method for calculating EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA can vary among companies. The amounts included in the EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA calculations, however, are derived from amounts included in the historical consolidated statements of operations. EBITDA, Segment EBITDA, Adjusted EBITDA, and Adjusted Segment EBITDA should not be considered as alternatives to net earnings (loss) or operating earnings (loss) as an indicator of the Company's operating performance, or as an alternative to operating cash flows as a measure of liquidity.

*About Kewaunee Scientific* 

Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks. The Company's corporate headquarters are located in Statesville, North Carolina. Sales offices are located in the United States, India, Saudi Arabia, and Singapore. Three manufacturing facilities are located in Statesville serving the domestic and international markets, and one manufacturing facility is located in Bangalore, India serving the local, Asian, and African markets.

Kewaunee Scientific's newly acquired subsidiary, Nu Aire, is a leading manufacturer of biological safety cabinets, CO2 incubators, ultralow freezers, and other essential laboratory products that complement the Kewaunee Scientific portfolio. Founded in 1971, Nu Aire's headquarters and manufacturing facilities are located in Plymouth, Minnesota, with additional manufacturing capabilities located in Long Lake, Minnesota. The Company also maintains a warehouse partnership in the Netherlands and OEM partnerships in China.

Learn more at the companies' websites, located at <u>https://www.kewaunee.com</u> and <u>https://www.nuaire.com/</u>.

*This press release contains statements that the Company believes to be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All* 

------

*statements other than statements of historical fact included in this press release, including statements regarding the Company's future financial condition, results of operations, business operations and business prospects, are forward-looking statements. Words such as "anticipate," "estimate," "expect," "project," "intend," "plan," "predict," "believe" and similar words, expressions and variations of these words and expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to known and unknown risks, uncertainties, assumptions, and other important factors that could significantly impact results or achievements expressed or implied by such forward-looking statements. Such factors, risks, uncertainties and assumptions include, but are not limited to: our ability to realize the benefits anticipated as a result of the Nu Aire acquisition; competitive and general economic conditions, including disruptions from government mandates, both domestically and internationally, as well as supplier constraints and other supply disruptions; changes in customer demands; technological changes in our operations or in our industry; dependence on customers' required delivery schedules; risks related to fluctuations in the Company's operating results from quarter to quarter; risks related to international operations, including foreign currency fluctuations; changes in the legal and regulatory environment; changes in raw materials and commodity costs; acts of terrorism, war, governmental action, and natural disasters and other Force Majeure events. The cautionary statements made pursuant to the Reform Act herein and elsewhere by us should not be construed as exhaustive. We cannot always predict what factors would cause actual results to differ materially from those indicated by the forward-looking statements. Over time, our actual results, performance, or achievements will likely differ from the anticipated results, performance or achievements that are expressed or implied by our forward-looking statements, and such difference might be significant and harmful to our stockholders' interest. Many important factors that could cause such a difference are described under the caption "Risk Factors," in Item 1A of our Annual Report on Form 10-K for the fiscal year ended April 30, 2025, which you should review carefully, and in our subsequent quarterly reports on Form 10-Q and current reports on Form 8-K. These reports are available on our investor relations website at <u>www.kewaunee.com</u> and on the SEC website at <u>www.sec.gov</u>. These forward-looking statements speak only as of the date of this document. The Company assumes no obligation, and expressly disclaims any obligation, to update any forward-looking statements, whether as a result of new information, future events or otherwise.*

------

**Kewaunee Scientific Corporation**

**Condensed Consolidated Statements of Operations**

*(Unaudited)*

*($ and shares in thousands, except per share amounts)*

---

| | | |
|:---|:---|:---|
| | **Three Months Ended<br>July 31,** | **Three Months Ended<br>July 31,** |
| | **2025** | **2024** |
| Net sales | $**71104** | $48393 |
| Cost of products sold | **50174** | 35905 |
| Gross profit | **20930** | 12488 |
| Operating expenses | **16120** | 9913 |
| Operating profit | **4810** | 2575 |
| Other income, net | **168** | 327 |
| Interest expense | **(1058)** | (472) |
| Profit before income taxes | **3920** | 2430 |
| Income tax expense | **761** | 192 |
| Net earnings | **3159** | 2238 |
| Less: Net earnings attributable to the non-controlling interest | **66** | 45 |
| Net earnings attributable to Kewaunee Scientific Corporation | $**3093** | $2193 |
| Net earnings per share attributable to Kewaunee Scientific Corporation stockholders |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | $**1.08** | $0.77 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | $**1.04** | $0.74 |
| Weighted average number of common shares outstanding |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | **2851** | 2849 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | **2963** | 2967 |

---

------

**Kewaunee Scientific Corporation**

**Condensed Consolidated Balance Sheets**

*($ in thousands)*

---

| | | |
|:---|:---|:---|
| | **July 31, 2025** | **April 30, 2025** |
| | **(Unaudited)** | |
| **<u>Assets</u>** | | |
| Cash and cash equivalents | $**19489** | $**14942** |
| Restricted cash | **952** | **2222** |
| Receivables, less allowances | **56897** | **62384** |
| Inventories | **34923** | **32849** |
| Prepaid expenses and other current assets | **4887** | **5966** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Current Assets | **117148** | **118363** |
| Net property, plant and equipment | **22781** | **23174** |
| Right of use assets | **12022** | **12965** |
| Deferred income taxes | **4211** | **3994** |
| Net intangible assets | **17447** | **17831** |
| Goodwill | **12487** | **12487** |
| Other assets | **7390** | **5840** |
| Total Assets | $**193486** | $**194654** |
| **<u>Liabilities and Stockholders' Equity</u>** |  |  |
| Short-term borrowings | $**495** | $**986** |
| Current portion of lease obligations | **3220** | **3371** |
| Current portion of financing liability | **807** | **788** |
| Current portion of term loan | **2903** | **2903** |
| Accounts payable | **26327** | **27033** |
| Other current liabilities | **16734** | **18631** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Current Liabilities | **50486** | **53712** |
| Long-term portion of lease obligations | **8156** | **8946** |
| Long-term portion of financing liability | **26420** | **26632** |
| Long-term portion of seller note | **24021** | **23537** |
| Long-term portion of term loan | **9686** | **10412** |
| Other non-current liabilities | **5848** | **5170** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Liabilities | **124617** | **128409** |
| Kewaunee Scientific Corporation Equity | **67078** | **64457** |
| Non-controlling interest | **1791** | **1788** |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Stockholders' Equity | **68869** | **66245** |
| Total Liabilities and Stockholders' Equity | $**193486** | $**194654** |

---

<br>